skip to Main Content

Progress Towards a Pan-Ebolavirus Treatment

  • May 11, 2016

In 2014, the alarm for the Zaire Ebola virus was sounded around the world—but there are other deadly ebolaviruses that cause identical symptoms, and they have even fewer treatment options. In a study publishing May 5 in Cell Reports, researchers…

Read More

IBT Presents Pan-Ebola and Pan-Filovirus Monoclonal Antibodies

  • July 22, 2015

Integrated BioTherapeutics, Inc. (IBT), a leader in infectious disease and filovirus research, today announced the discovery of novel Pan-Ebola and Pan-Filovirus monoclonal antibodies (mAbs). IBT scientists presented the new mAbs at the 7th International Symposium on Filoviruses held in Washington,…

Read More

Integrated BioTherapeutics Partners With Chembio

  • July 22, 2015

Integrated BioTherapeutics Partners With Chembio to Develop Point-of-Care Diagnostic Tests for Ebola and Febrile Illness Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, today announced that it has entered into an exclusive agreement with Integrated BioTherapeutics, Inc. (IBT), a biotechnology…

Read More

IBT Secures Another SBIR to Discover Staph Vaccines

  • July 22, 2015

A Novel Paradigm for Fighting Staphylococcal Infections and Their Complications The pathogenicity of Staphylococcus aureus (S. aureus) is dependent on a wide range of virulence factors including cell surface proteins, polysaccharides, and secreted toxins. Surface antigens mediate the attachment of…

Read More

IBT and Stanford Awarded STTR

  • July 22, 2015

IBT and Stanford Awarded STTR for HCV Therapeutic Antibodies Integrated BioTherapeutics (IBT) and Stanford University have been jointly awarded a $300,000 Small Business Technology Transfer (STTR) grant from the National Institute of Allergy and Infectious Diseases of the National Institutes…

Read More

New Bioterrorism Vaccine Gets First Test In Humans

  • July 22, 2015

Integrated BioTherapeutics (IBT) announces the initiation of a Phase 1 clinical trial testing the safety and immunogenicity of its staphylococcal enterotoxin B vaccine "STEBVAX" in healthy adults. This trial, marking the first time a superantigen vaccine has been administered to…

Read More

SBIR Award: Integrated BioTherapeutics

  • July 22, 2015

SBIR Award: Integrated BioTherapeutics to Create Therapeutic Multi-Specific Antibodies Using Technology from Zyngenia Integrated Biotherapeutics (IBT) has been awarded a Phase I Small Business Innovative Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division…

Read More

SBIR Award: Integrated BioTherapeutics

  • July 22, 2015

Integrated BioTherapeutics (IBT) has been awarded a Phase I Small Business Innovative Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the NIH. The company will receive $550,000 for work to take place…

Read More
Back To Top
×Close search
Search